CD133 Epitopes
AssigneeCedars-Sinai Medical Center
InventorsJohn S. Yu, Keith L. Black, Gentao Liu
Life of this patent
Estimating the term…
Abstract
An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.
Claims20
An isolated immunogen comprising an isolated peptide of 800 amino acid residues or fewer comprising the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions.
An isolated immunogen comprising an isolated peptide of 800 amino acid residues or fewer comprising an amino acid sequence having the formula:
- (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13).
An isolated polynucleotide comprising a nucleic acid sequence encoding a peptide of 800 amino acid residues or fewer comprising the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions.
A method for treating a cancer in a patient, the method comprising administering to the patient a composition comprising antigen-presenting cells, wherein the antigen presenting cells present on their surface a peptide epitope comprising the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions.
Dependencies are inferred from the claim text.